Medicare Enrolled

Dr. Richard Jimenez, MD

Rheumatology · Bothell, WA
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Speaking/Promotional
1909 214TH ST SE STE 211, Bothell, WA 98021
4252482626
In practice since 2006 (20 years)
NPI: 1366484040 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Jimenez from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Jimenez? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Jimenez

Dr. Richard Jimenez is a rheumatology specialist in Bothell, WA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Jimenez performed 7,005 Medicare services across 351 unique beneficiaries.

Between the years covered by Open Payments, Dr. Jimenez received a total of $216,313 from 46 pharmaceutical and/or device companies across 1067 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Jimenez is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice ▲ Top 20% volume in WA $216,313 industry payments

Medicare Practice Summary

Medicare Utilization ↗
7,005
Medicare services
Top 20% in WA for rheumatology
351
Unique beneficiaries
$29
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~350 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Infliximab infusion (Remicade)
An injection of infliximab, excluding biosimilar versions, administered in a 10 mg dose.
4,050 $26 $170
Denosumab injection (Prolia/Xgeva) 1,981 $18 $35
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
315 $87 $333
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
220 $104 $342
Normal saline infusion, 250 cc
Administration of 250 cubic centimeters of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater fluid.
215 $1 $5
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
102 $22 $77
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
57 $124 $423
Drug injection, under skin or into muscle
A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle.
35 $10 $56
New patient office visit, complex (60-74 min) 15 $170 $658
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
15 $62 $228
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
64.0% high complexity
30.2% medium
5.7% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$216,313
Total received (2018-2024)
Avg $30,902/year across 7 years
Top 4% in WA for rheumatology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
46
Companies
1,067
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$180,349 (83.4%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$25,297 (11.7%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,667 (4.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$12,466
2023
$9,732
2022
$13,770
2021
$6,725
2020
$25,213
2019
$72,920
2018
$75,488

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Amgen Inc.
$10,329
ABBVIE INC.
$595
Janssen Biotech, Inc.
$375
Novartis Pharmaceuticals Corporation
$185
GlaxoSmithKline, LLC.
$114
GENZYME CORPORATION
$96
Lilly USA, LLC
$88
Boehringer Ingelheim Pharmaceuticals, Inc.
$88
AstraZeneca Pharmaceuticals LP
$84
SOBI, INC
$81
Alexion Pharmaceuticals, Inc.
$81
Aurinia Pharma U.S., Inc.
$77
Kiniksa Pharmaceuticals International, plc
$66
Genentech USA, Inc.
$62
E.R. Squibb & Sons, L.L.C.
$54
UCB, Inc.
$52
ANI Pharmaceuticals, Inc.
$22
Radius Health, Inc.
$18
Top 3 companies account for 90.6% of 2024 payments
All-time payments by company (2018-2024) ›
Novartis Pharmaceuticals Corporation
$51,570
Amgen Inc.
$39,558
Celgene Corporation
$30,478
Horizon Therapeutics plc
$13,199
AbbVie, Inc.
$12,606
Horizon Pharma plc
$12,447
Mallinckrodt LLC
$10,045
Mallinckrodt Enterprises LLC
$9,437
Janssen Biotech, Inc.
$9,134
Ironwood Pharmaceuticals, Inc
$6,875
NOVARTIS PHARMACEUTICALS CORPORATION
$5,050
UCB, Inc.
$3,042
Alexion Pharmaceuticals, Inc.
$2,759
Mallinckrodt Hospital Products Inc.
$1,738
ABBVIE INC.
$1,657
Genentech USA, Inc.
$1,362
E.R. Squibb & Sons, L.L.C.
$758
PFIZER INC.
$676
GlaxoSmithKline, LLC.
$647
Lilly USA, LLC
$597
Radius Health, Inc.
$398
AstraZeneca Pharmaceuticals LP
$322
AbbVie Inc.
$263
SOBI, INC
$263
Boehringer Ingelheim Pharmaceuticals, Inc.
$192
Sobi, Inc
$186
Regeneron Healthcare Solutions, Inc.
$180
Takeda Pharmaceuticals U.S.A., Inc.
$152
Aurinia Pharma U.S., Inc.
$110
GENZYME CORPORATION
$110
Hikma Pharmaceuticals USA
$74
Kiniksa Pharmaceuticals International, plc
$66
Teva Pharmaceuticals USA, Inc.
$48
Sandoz Inc.
$45
Sentynl Therapeutics, Inc.
$44
Bioventus LLC
$35
Kiniksa Pharmaceuticals, Ltd.
$28
ANI Pharmaceuticals, Inc.
$22
Ultragenyx Pharmaceutical Inc.
$22
Kyowa Kirin, Inc.
$20
West-Ward Pharmaceuticals
$20
Alfasigma USA, Inc.
$19
Gilead Sciences, Inc.
$19
SANOFI-AVENTIS U.S. LLC
$18
SUN PHARMACEUTICAL INDUSTRIES INC.
$17
Janssen Scientific Affairs, LLC
$9
Top 3 companies account for 56.2% of all-time payments
Associated products mentioned in payments ›
ACTHAR · AJOVY · AMJEVITA · Actemra · Aimovig · Arcalyst · BENLYSTA · Bimzelx · CHANTIX · COLOGUARD · COLOGUARD DNA CAPTURE REAGENTS · COSENTYX · CYLTEZO · Cimzia · Crysvita · DUPIXENT DUPILUMAB INJECTION · DUZALLO · Durolane · EVENITY · Enbrel · FORTEO · HUMIRA · HYRIMOZ · Humira · ILARIS · INFLECTRA · Ilumya · KEVZARA · KEVZARA SARILUMAB INJECTION · KINERET · KRYSTEXXA · Kineret · LUPKYNIS · LYRICA · Levorphanol · Levorphanol Tartrate · Mitigare · ORENCIA · Otezla · PENNSAID · PURIFIED CORTROPHIN GEL · Prolia · RAYOS · REMICADE · REYVOW · RINVOQ · Repatha · Rinvoq · Rituxan · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · STELARA · STRENSIQ · Strensiq · TALTZ · TAVNEOS · TEPEZZA · TREMFYA · Tavneos · Tymlos · Uloric · XELJANZ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (83%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in rheumatology and does not inherently indicate bias, but patients may wish to be aware. Total industry engagement is in the top 4% for rheumatology in WA.

Looking for a rheumatology specialist in Bothell?
Compare rheumatologists in the Bothell area by procedure volume, costs, and industry payment transparency.
Browse rheumatologists nearby

Geographic Context

Rheumatologists within 10 mi
99
Per 100K population
11.9
County median income
$107,982
Nearest hospital
EVERGREENHEALTH MEDICAL CENTER
5.3 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Jimenez is a mixed practice specialist, with above-average Medicare volume (top 20% in WA), with speaking/promotional industry engagement in the top 4% of WA peers, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Jimenez experienced with infliximab infusion (remicade)?
Based on Medicare claims data, Dr. Jimenez performed 4,050 infliximab infusion (remicade) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Jimenez receive payments from pharmaceutical companies?
Yes. Dr. Jimenez received a total of $216,313 from 46 companies across 1,067 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Jimenez's costs compare to other rheumatologists in Bothell?
Dr. Jimenez's average Medicare payment per service is $29. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Jimenez) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →